echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Subcutaneous injection of PD-L1 antibody US Phase 1 clinical data published The Oncologist

    Subcutaneous injection of PD-L1 antibody US Phase 1 clinical data published The Oncologist

    • Last Update: 2021-06-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Pharmaceutical Guanlan

    On May 28th, a recombinant humanized PD-L1 single-domain antibody (Envolimab, KN035) strategically cooperated by Corning Jereh, Sildi Medicine, and Simcere, was published in The Oncologist, an internationally renowned medical journal.


    According to the press release, Envolimab injection is the PD-L1 single-domain antibody Fc fusion protein developed by Corning Jereh.


    In November 2020, Envolimab submitted a new drug marketing application to the China National Medical Products Administration (NMPA).


    The online publication this time is the first phase 1 clinical trial of Envolimab in humans, and the indication is for advanced solid tumors.


    ▲Tumor response observed in the study (Source of screenshots: Reference [2])

    The results of the test showed that a total of 3 subjects had confirmed partial remission, and the therapeutic response was observed as low as 0.


    During the dose-escalation phase, no dose-limiting toxicity was observed, and the maximum tolerated dose was not reached.


    In the dose exploration phase, when 300 mg Q4W is used, the steady-state half-life can be as long as 23 days.


    In terms of safety, the most common treatment emergency adverse events were fatigue (29%), nausea (18%), diarrhea (14%) and hypothyroidism (14%).


    Note: The original text has been deleted

    Reference materials:

    [1] US Phase I clinical data of envolimab was published in The Oncologist.


    [2]First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.